Business
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharma
About this update from Aon Plc
[{"type":"image","alt":"Oculis Holding AG","displaySize":"","headline":null,"caption":"Oculis Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":198,"height":67,"url":"https://media.zenfs.com/en/globenewswire.com/8aca71b5070568d4906f198837bc6857"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iuy6vbbeZZeiKgz96e65CQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8aca71b5070568d4906f198837bc6857","width":198,"height":67},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/iuy6vbbeZZeiKgz96e65CQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8aca71b5070568d4906f198837bc6857","width":198,"height":67}},"lazy":false},{"type":"text","content":"ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)","length":232,"tagName":"p"},{"type":"text","content":"Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION","length":128,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast at 8:30 AM ET today","length":63,"tagName":"p"},{"type":"text","content":"Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a positive meeting with the U.S. Food and Drug Administration (FDA).","length":385,"tagName":"p"},{"type":"text","content":"Privosegtor is a new peptoid small molecule candidate with the potential to become the first neuroprotective therapy for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potential in other neuro-ophthalmic and neurological diseases. Following FDA feedback, the company is starting the PIONEER program this year, which will include three pivotal trials to support registration plans for Privosegtor in AON and NAION.","length":465,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"PIONEER-1 trial in AON (Q4 202...